IgA nephropathy: the lectin pathway and implications for targeted therapy

Area of Science:

• Nephrology
• Immunology
• Complement System Biology

Background:

• Immunoglobulin A nephropathy (IgAN) frequently progresses to kidney failure despite supportive care.
• Understanding IgAN pathophysiology is crucial for developing targeted therapies.
• The complement system, especially lectin and alternative pathways, is a key mediator of kidney injury in IgAN.

Purpose of the Study:

• To review the role of the lectin pathway in IgAN pathogenesis.
• To examine the scientific and clinical evidence for lectin pathway involvement in IgAN.
• To explore the therapeutic potential of lectin pathway inhibition in IgAN.

Main Methods:

• Review of scientific literature and clinical evidence.
• Analysis of kidney biopsy findings in IgAN patients.
• Examination of the association between lectin pathway components and disease severity.

Main Results:

• Glomerular deposition of mannan-binding lectin (MBL) and IgA1 occurs in up to 50% of IgAN patients.
• Lectin pathway activation correlates with severe glomerular damage, proteinuria, and hematuria.
• Emerging evidence links collectin-11 and the lectin pathway to tubulointerstitial fibrosis in IgAN.

Conclusions:

• The lectin pathway plays a significant role in IgAN progression and kidney injury.
• Targeting the lectin pathway represents a promising therapeutic avenue for IgAN.
• Further research into lectin pathway inhibition is warranted for IgAN treatment.